In this article, we will discuss Anlotinib (Pharmacokinetics-4). So, let’s get started.
There have been two phase I clinical trials investigating the pharmacokinetic properties of anlotinib. In a phase I clinical study in China, the plasma concentration of anlotinib increased significantly 1 h after dosing in
most patients, confirming that anlotinib was rapidly absorbed from the intestines. The peak plasma concentration (Cmax) and area under the concentration-time curve to 120 h post-dose (AUC0–120 h) of anlotinib both
increased with increasing doses from 5 to 16 mg anlotinib/person, while the dose proportionality was indeterminate. After a dose of 16 mg anlotinib/person, the mean Cmax of anlotinib was 10.5 ± 2.9 ng/mL. The time taken to achieve Cmax (Tmax) and the elimination half-life (t 1/2) of anlotinib were 4–11 h and 96 ± 17 h following dosing, respectively.